Call Us Now: (240) 429 2177

Health

Largest clinical trial in Africa to treat mild COVID-19 cases
November 25, 2020 | 0 Comments

By Jorge Joaquim

13 African countries and an international network of research institutions have joined forces to launch the largest COVID-19 clinical trial in mild-to-moderate outpatients in Africa.  The ANTICOV clinical trial aims to respond to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalization that could overwhelm fragile and already overburdened health systems in Africa.

The clinical trial will be carried out at 19 sites in 13 countries by the ANTICOV consortium, which includes 26 prominent African and global research and development (R&D) organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi), an international non-profit drug research and development (R&D) group with extensive partnerships in Africa.

“There is a need for large clinical trials in Africa for COVID-19 to answer research questions that are specific to an African context,” said Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention. “African countries have mounted an impressive response so far to COVID-19 and now is the time to prepare for future waves of the disease”.

ANTICOV is an open-label, randomised, comparative, ‘adaptive platform trial’ that will test the safety and efficacy of treatments in 2,000 to 3,000 mild-to-moderate COVID-19 patients in Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo (DRC), Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda. ANTICOV aims to identify early treatments that can prevent progression of COVID-19 to severe disease and potentially limit transmission.

“Africa has for the most part avoided the large-scale mortality seen in other countries, but with lockdowns ending and borders opening, we need to be prepared” said Dr Borna Nyaoke-Anoke, Senior Clinical Project Manager at DNDi, which is also the sponsor for clinical trials in the DRC, Kenya, and Sudan.  “We need research here in Africa that will inform policies and test-and-treat strategies, so that as clinicians we can give the best options to people with COVID-19.”

Initially, ANTICOV will focus on drugs where large-scale randomized clinical trials could provide missing efficacy data in mild-to-moderate patients. The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.

Read More
Covid-19 en RDC : 55 nouveaux cas enregistrés mardi
November 25, 2020 | 0 Comments

Depuis le début de l’épidémie déclarée le 10 mars 2020, le cumul des cas est de 12.365, dont 12.364 cas confirmés et 1 cas probable. Au total, il y a eu  331 décès  (330 cas confirmés et 1 cas probable) et 11.433 personnes guéries.   

  • 55 nouveaux cas confirmés, dont 46 à Kinshasa, au Kongo Central, au Sud-Kivu et dans le Haut-Katanga ;
  • 278 échantillons testés ;
  • Aucun nouveau décès parmi les cas confirmés des CTCo ;
  • Aucune nouvelle personne n’est sortie guérie dans les CTCo, ni parmi les patients suivis à domicile.  

N.B : Le test Covid-19 est gratuit pour tout le monde en République démocratique du Congo. Cependant, le test des voyageurs est payant à 30 dollars américains.
 
*Les 22 provinces touchées :
 

  • Kinshasa             :              9.342 cas ;
  • Nord-Kivu           :              1.174 cas ;
  • Kongo Central   :              548 cas ;
  • Haut-Katanga    :              377 cas ;
  • Sud-Kivu              :              351 cas ;
  • Ituri                      :              183 cas ;
  • Lualaba               :              131 cas ;
  • Haut-Uélé           :              92 cas ;
  • Tshopo                :              68 cas ;
  • Nord-Ubangi     :              38 cas ;
  • Equateur            :              22 cas ;  
  • Sud-Ubangi        :              7 cas ;
  • Kwilu                   :              6 cas ;
  • Tanganyika        :              6 cas ;
  • Bas-Uélé             :              5 cas ;
  • Kasaï Oriental   :              4 cas ;
  • Maniema            :              4 cas ;
  • Tshuapa              :              2 cas.
  • Haut-Lomami    :              1 cas :
  • Kasaï                    :              1 cas ;
  • Kasaï Central     :              1 cas ;
  • Kwango                              :              1 cas ;

L’article Covid-19 en RDC : 55 nouveaux cas enregistrés mardi est apparu en premier sur Matininfos.NET – Information de la RDC en toute impartialité.

Source: Matininfos

Source : African Media Agency (AMA)

Read More
Battling the Coronavirus across Angola
November 25, 2020 | 0 Comments

UK manufacturer joins the fight against disease across Angola.

Eduardo Sierra Torres, With and MP100 wrapped and ready to ship.
Eduardo Sierra Torres, With and MP100 wrapped and ready to ship.

As Covid19 continues to make headlines it is important to recognise the work that International Aid Agencies continue to complete. Working across developing countries, often with limited infrastructure to establish facilities to enable the safe disposal of medical waste.

For many years now Addfield has worked side by side with many of these organisations to combat viral outbreaks in developing regions. Delivering comprehensive solutions across varying scales treating endemics, and epidemics, some newsworthy whilst others were not so. This year however the word pandemic has been firmly on everyone’s lips and you cannot go five minutes without hearing about the Coronavirus once again.

It is important to not forget that Covid19 is not the only infectious disease that is fatally infectious. In this instance AFG SA, based in Portugal and experts in the sale of medical equipment approached leading medical incineration manufacturers Addfield based in the UK. AFG through their Angola subsidiary Acail Angola asked Addfield to support them on a project for the Angolan Ministry of Health to supply and install 5 medical waste machines, to not only manage the additional waste created through combatting the Covid19 outbreak but also the continuing impact of Malaria and Tuberculosis across 5 field hospitals, located in Nzeto, Huila, Cunene, Dundo and Cabinda.

Coronavirus is currently not the biggest killer in Angola. Records indicate 333 confirmed deaths from the Coronavirus as of the middle of November 2020. Compared to Malaria which is responsible for an average of 12,000 deaths a year placing Angola in the top 10 countries most affected by the disease. As such in addition to supporting in the management of the Coronavirus these incinerators will also prove essential pieces of equipment to combat other diseases for many years to come.

For this project they selected 5 MP100 Medical/Pathological Incinerators. The MP range has proven itself to be a highly reliable solution for many aid agencies and NGO’s for treating waste in remote locations. Being both highly compact whilst also delivering quality and reliable medical waste disposal.

Beyond the visible impact of contagious diseases, there is also a hidden threat across Angola. Poverty is a growing problem, leading many families according to reports to subsist from scavenging in openly dumped garbage, which can include medical waste in some regions. This is another benefit of these machines as they will remove the hazardous waste and the health care risks from the ecosystem protecting the environment alongside its residents.

“A lot of investment is taking place across Angola to reduce these issues and reduce the numbers of deaths from avoidable diseases such as Malaria and Tuberculosis which are blighting the country and we are proud to be able to play a small but important part in this as we know that our machines will stand the test of time and could be supporting these 5 communities for more than 20 years a fantastic improvement in the quality of life and a great legacy for us in the region.” Eduardo Sierra Torres, International Sales, Addfield Environmental Systems.

For years now Addfield has been recognised as the name to trust in medical waste disposal. Delivering machines to suit the smallest laboratory up to several thousand bed hospitals to safely dispose of harmful waste. This project is yet another success for Addfield not only for helping to support international health but also through being yet another new country to add onto our roster of countries that have invested in one of our solutions.  Following the success of this project we are already in negotiations for future projects.

Read More
RCSI and BD partner to expand access to paediatric surgery in Sub-Saharan Africa
November 25, 2020 | 0 Comments
Professor Eric Borgstein is a leading Malawian pediatric surgeon

DUBLIN, Nov. 24, 2020 – The RCSI Institute of Global Surgery and global medical technology company, BD (Becton, Dickinson and Company) (NYSE: BDX), today announce KidSURG, a joint initiative aimed at significantly improving paediatric surgical services across Southern Malawi.

Created in collaboration with leading Malawian paediatric surgeon,Professor Eric Borgstein,theKidSURG initiative will develop a paediatric surgical network in Southern Malawi, to expand surgical access to 8 million children. The initiative will also seek to develop and share optimal models for replicating this initiative in other countries. BD has donated $500,000 in cash and surgical products to support the initiative.

Malawi is a region within Africa that faces a catastrophic deficit in surgical care access. The country’s unmet need for surgical care is estimated to be 41 million cases per year, resulting in a greater number of deaths than those resulting from TB, HIV and Malaria combined.

Through the KidSURG initiative, RCSI worked in partnership with Professor Borgstein and his team in Malawi to identify the greatest challenges when it comes to expanding surgical access. Together they will work to reduce unnecessary childhood mortality by addressing the shortfall in surgical equipment and medical expertise within district hospitals in the region. The KidSURG initiative will train healthcare workers to deliver high-quality, pre-referral care for complex paediatric surgical patients, and deliver safe surgery for some of the most common surgical procedures needed by children.

The initiative will also direct the development of a specialist mentor network, through which paediatric surgeons in central hospitals can provide immediate advice on patient management to regional district hospitals. Additionally, the project will supply custom-made paediatric surgical toolboxes, sponsored by BD, providing critical equipment needed to operate safely on children.

Following initial roll out, RCSI will evaluate opportunities to scale-up and expand the initiative elsewhere in a cost effective manner, ensuring that its impact is maximised.

Professor Eric Borgstein, Consultant Paediatric Surgeon at the Queen Elizabeth Central Hospital, Malawi said: The KidSURG initiativeis a powerful example of practical and effective support that will help increase expertise in district hospitals across MalawiI welcome this important collaboration with RCSI and extend my sincere thanks to BD for supporting our critical work on the ground.”

Professor Mark Shrime, O’Brien Chair of Global Surgery at RCSI, said: For over ten years, RCSI has pioneered and accelerated change to provide solutions to the surgical deficit, focusing on low and middle-income countries. We are proud to announce this partnership with BD which will significantly reduce mortality rates for children.”

Greg Quinn, Director of Public Policy & Advocacy at BD, said: “BD has strong heritage of facilitating best-practice patient and healthcare worker safety across the world. This important partnership with our RCSI colleagues and local Malawi professionals will enable the best surgical outcomes and the safest possible interventions for children in Malawi, and we also hope it will become a model for expanding safe surgical access to children in other developing nations as well.”

Building on extensive experience in surgical training, education and research partnerships in Africa, the RCSI Institute of Global Surgery works with local partners to develop sustainable surgical care systems in low and middle-income countries. The Institute has a dual focus: capacity-building to alleviate the surgical burden, and high impact research to set the foundation for greater growth.

For nine years RCSI researchers have led the COST and SURG-Africa global surgery consortia working to develop, implement and evaluate sustainable training models in which local physicians and non-physician clinicians are trained to deliver safe surgery in rural hospitals with the support of consultant surgeons from within the region.

RCSI University of Medicine and Health Sciences is ranked first in the world for ‘Good Health and Well-being’ in the Times Higher Education University Impact Rankings 2020The University’s leading global position in this category reflects RCSI’s singular focus on improving human health, for the benefit of patients and communities across the globe.

About RCSI
Ranked number one globally for Good Health and Well-being in the Times Higher Education (THE) University Impact Rankings 2020, RCSI University of Medicine and Health Sciences is an international not-for-profit university, with its headquarters in Dublin.

RCSI is exclusively focused on education and research to drive improvements in human health worldwide. It is among the top 250 universities worldwide in the THE World University Rankings (2021) and is ranked second among the universities in Ireland. Its research is ranked first in Ireland for citations. RCSI has been awarded Athena SWAN Bronze accreditation for positive gender practice in higher education.

Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. In support of the UN Sustainable Development Goals to promote health and wellbeing, these academics, clinicians and researchers are willing to engage with the media in their area of expertise so they can empower people with information that leads them to better health.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

About Professor Eric Borgstein
Professor Eric Borgstein is a Malawian paediatric surgeon, who serves as a Professor of Surgery at the University of Malawi College of Medicine, and as Consultant Paediatric Surgeon at the Queen Elizabeth Central Hospital (QECH), the largest public hospital in Malawi.

He is Director of the Mercy James Centre for Paediatric Surgery and Intensive Care; a recently established specialist centre for service provision and training in paediatric surgery and paediatric critical care at the QECH. He currently Secretary General of the College of Surgeons of East, Central and Southern Africa (COSECSA)

Read More
Africa’s First Online Clinical Trial Community established
November 23, 2020 | 0 Comments

By Wallace Mawire

Prof Tom Kariuki, Director of Programmes/AESA Director, African Academy of Sciences (AAS)
Prof Tom Kariuki, Director of Programmes/AESA Director, African Academy of Sciences (AAS)

The Clinical Trial Community (CTC)  a versatile, comprehensive, and accessible platform providing quick and real-time visibility of African clinical trials sites, capacity, and capability has been set up.

 The first of its kind on the continent, the CTC platform also links relevant initiatives that support the conduct of trials, enables timely ethics and regulatory review and provides country level guidelines for import/export of relevant clinical supplies and bio-specimens. The platform aims to reduce bias in funding across countries and disease areas and promote synergy and efficiency across strategic funders in the product development ecosystem. Although this project was already underway, the worldwide rush to develop diagnostics, drugs and vaccines for COVID-19 provides a sense of urgency to develop this one-stop source of information for operational logistics in conducting clinical trials in Africa.

Research capabilities in Africa are improving with more robustly trained local researchers working in better equipped facilities. This ensures that African countries lead and collaborate in all phases of early to late-stage clinical trials. The CTC saves on cost and time associated with landscape analysis and although it captures African clinical trials at the start, the aim is to expand the community to other parts of the world.

CTC, an output of the Coalition for African Research and Innovation (CARI), is supported through a global partnership led by Johnson & Johnson, the US National institutes of Health (NIH), Wellcome, the Bill & Melinda Gates Foundation and World Economic Forum (WEF). CARI, conceived as an ambitious platform by African and Global partners and implemented through the Alliance for Accelerating Excellence in Science in Africa (AESA), is a well-funded, strongly supported and highly coordinated platform that leverages resource mobilisation for investment, undertakes strategic advocacy to harness leadership and fosters systematic collaboration to achieve outcomes that would help more Africans lead better lives sooner.

Other partners of CTC instrumental in the development of the clinical trials database include the World Health Organization (WHO) created African Vaccine Regulatory Forum (AVAREF), the Coalition for Epidemic Preparedness Innovations (CEPI), the Institute for Health Metrics and Evaluation (IHME), Pan African Clinical Trials Registry (PACTR), the European and Developing Countries Clinical Trials Partnership (EDCTP), the Africa Centres for Disease Control and Prevention (Africa CDC) and Drugs for Neglected Diseases Initiative (DNDi).

Announcing the establishment of the clinical trial community Prof Tom Kariuki, Director of Programmes/AESA Director, African Academy of Sciences (AAS) said, “The incredible diversity in Africa is unlike anywhere else in the world. The continent is made up of many cultures and ethnic groups whose genetic makeup impact clinical trial outcomes. It is very important that more trials are conducted on African soil. Unfortunately, the process of finding experienced investigators, trial centres/sites, existing and future trials, and determining the in-country processes and regulations to be followed to achieve correct regulatory approvals has been very difficult to do. With the CTC platform, researchers and possible funders will have a comprehensive source of intelligence on country-level clinical trial capabilities and processes which will aid in decision making.”

Dirk Gille, Vice President, R&D Capacity Development Leader, Global Public Health at Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson added: “The Clinical Trials Community platform will be an incredibly valuable tool in the successful execution of clinical trials in Africa. Bringing together essential information on clinical trial site capabilities, coupled with regional disease burden, will help enable the implementation of trials in the right centres and regions. While the ability to connect with scientists through the platform will further drive efficiencies and create opportunities.  Ultimately, this should contribute to an increase in the number of clinical trials on the continent and, in time, accelerate access to innovative medicines for patients in Africa and around the world.”

“Sustained efforts to expedite development of clinical interventions against diseases rampant in Africa requires good capacity and networking of scientists and their trial sites. CTC couldn’t have been started at a better time when the world is challenged by epidemics on top of the high infectious diseases and rising non-communicable disease burden in Africa. The CTC will make African scientists and their sites more visible and reachable for concerted response in development of clinical interventions the continent and the world urgently need,” said Dr Thomas Nyirenda, EDTCP Strategic Partnerships & Capacity Development Manager, who is also chair of the CTC Advisory Committee providing strategic guidance to the AESA programme.

Diadié Maiga, the Regional Vaccine Regulation Officer at AVAREF, says: “We have seen a noticeable gap in the availability of information to trial sponsors and trialists, which is crucial to ensure clinical trials take place and for participants to be recruited. By showcasing the regulatory and ethical requirements, approval processes, timelines, and guidelines for conducting trials in the different countries across the continent, the CTC is a value add to the landscape that will promote knowledge sharing, awareness, trust, confidence and hopefully participation in clinical trials for the ultimate benefit of African people.”
 
“As key partners of the COVID-19 Vaccine Clinical Trial (CONCVACT) consortium, the Africa CDC aims to ensure that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates for the African population so once vaccines are formally approved, they can be rolled out in Africa with confidence about their impact. The overlaid trial sites, country regulatory processes, and diseases burden data on display on the African map provided on the CTC platform will set the criteria for trial site selection guidance to potential clinical trial sponsors,” Nicaise Ndembi, Chief Science Advisor, Africa Centre for Disease Control and Prevention (Africa CDC).

“The CTC and partners are committed to supporting, enabling and accelerating investment in clinical and translational research capacity in Africa to effectively respond to disease outbreaks, reduce preventable deaths, strengthen productivity, improve quality of life, and to address countries public health needs. The recent outbreak of Covid-19 has shown us how important this type of collaboration really is,” says Dr Jenniffer Mabuka, CTC Consultant.

Read More
RDC : Vital Kamerhe refait une crise au centre Nganda
November 23, 2020 | 0 Comments

Le directeur de cabinet du chef de l’État Félix Antoine Tshisekedi, a fait une crise depuis la matinée de ce lundi 23 novembre 2020 au centre de santé Nganda dans la commune de Kintambo à kinsha à l’hôpital où il se trouve.

« Depuis dimanche soir, il avait des problèmes sérieux de respiration« , évoque une source proche de Vital Kamerhe.

Longtemps interné pour des raisons de santé, le président national de l’Union pour la nation congolaise UNC, a été évacué de sa cellule de la prison de Makala depuis 4 mois pour raisons de santé.

 »Malgré cette remise en liberté, son état ne s’améliore toujours pas », indiquent ces proches qui demandent à ce que ce dernier quitte le sol congolais pour l’étranger afin qu’il bénéficie des soins appropriés.

Depuis plus de 4 mois, cette demande n’a jamais trouvé échos auprès des décideurs du pays.

Jules Ninda

L’article RDC : Vital Kamerhe refait une crise au centre Nganda est apparu en premier sur Matininfos.NET – Information de la RDC en toute impartialité.

Source: Matininfos

Source : African Media Agency (AMA)

Read More
Covid-19 en RDC : 59 nouveaux cas, 1 décès et 43 guéris samedi
November 22, 2020 | 0 Comments

Depuis le début de l’épidémie déclarée le 10 mars 2020, le cumul des cas est de 12.239, dont 12.238 cas confirmés et 1 cas probable. Au total, il y a eu  328 décès  (327 cas confirmés et 1 cas probable) et 11.343 personnes guéries.

  • 59 nouveaux cas confirmés, dont 54 à Kinshasa, au Kongo central, à l’Equateur et au Sud-Kivu ;
  • 407 échantillons testés ;
  • nouveau décès des cas confirmés dans les CTCo à Kinshasa ;
  • 43 nouvelles personnes sorties guéries des CTCo et chez les patients suivis à domicile, dont 42 à Kinshasa et dans le Haut- Katanga.

 *Les 22 provinces touchées :
 

  • Kinshasa             :              9.227 cas ;
  • Nord-Kivu           :              1.174 cas ;
  • Kongo Central   :              542 cas ;
  • Haut-Katanga    :              376 cas ;
  • Sud-Kivu             :              349 cas ;
  • Ituri                      :              183 cas ;
  • Lualaba               :              130 cas ;
  • Haut-Uélé           :              92 cas ;
  • Tshopo                :              68 cas ;
  • Nord-Ubangi     :              37 cas ;
  • Equateur            :              22 cas ;  
  • Sud-Ubangi        :              7 cas ;
  • Kwilu                   :              6 cas ;
  • Tanganyika        :              6 cas ;
  • Bas-Uélé             :              5 cas ;
  • Kasaï Oriental   :              4 cas ;
  • Maniema            :              4 cas ;
  • Tshuapa              :              2 cas.
  • Haut-Lomami    :              1 cas :
  • Kasaï                    :              1 cas ;
  • Kasaï Central     :              1 cas ;
  • Kwango                              :              1 cas ;

 
N.B : Le test Covid-19 est gratuit pour tout le monde en République démocratique du Congo. Cependant, le test des voyageurs est payant à 30 dollars américains.

*/!\ Les données présentées dans ce tableau sont susceptibles de changer ultérieurement, après investigations approfondies et après redistribution des cas et décès dans leurs zones de santé respectives.*

L’article Covid-19 en RDC : 59 nouveaux cas, 1 décès et 43 guéris samedi est apparu en premier sur Matininfos.NET – Information de la RDC en toute impartialité.

Source: Matininfos

Source : African Media Agency (AMA)

Read More
Covid-19 en RDC : 121 nouveaux cas confirmés, dont 104 à Kinshasa, 8 au Nord-Kivu et 8 dans le Sud-Kivu jeudi
November 20, 2020 | 0 Comments

Depuis le début de l’épidémie déclarée le 10 mars 2020, le cumul des cas est de 12.129, dont 12.128 cas confirmés et 1 cas probable. Au total, il y a eu  324 décès  (323 cas confirmés et 1 cas probable) et 11.242 personnes guéries.   

  • 121 nouveaux cas confirmés, dont 104 à Kinshasa, au Nord-Kivu et dans le Sud-Kivu ;
  • 385 échantillons testés ;
  • nouveau décès des cas confirmés dans les CTCo ;
  • 27 nouvelles personnes sorties guéries des CTCo et chez les patients suivis à domicile, dont 20 à Kinshasa, au Kongo Central, dans le Haut- Katanga et au Nord-Kivu ;
  • Harmonisation des cas confirmés en date du 18 novembre 2020 : 
  • Kinshasa                  : 9019 contre 9021 :
  • Kongo Central            : 539 contre 542 ;
  • Sud Kivu                  : 340 contre 336 ;
  • Lualaba                     : 130 contre 128 ;
  • Tshuapa                    : 2     contre 1. 

N.B : Le test Covid-19 est gratuit pour tout le monde en République démocratique du Congo. Cependant, le test des voyageurs est payant à 30 dollars américains.

*Les 22 provinces touchées :
 

  • Kinshasa              :              9.123 cas ;
  • Nord-Kivu           :              1.174 cas ;
  • Kongo Central   :              539 cas ;
  • Haut-Katanga    :              376 cas ;
  • Sud-Kivu             :              347 cas ;
  • Ituri                      :              183 cas ;
  • Lualaba               :              130 cas ;
  • Haut-Uélé           :              92 cas ;
  • Tshopo                :              68 cas ;
  • Nord-Ubangi     :              37 cas ;
  • Equateur            :              21 cas ;  
  • Sud-Ubangi        :              7 cas ;
  • Kwilu                   :              6 cas ;
  • Tanganyika        :              6 cas ;
  • Bas-Uélé             :              5 cas ;
  • Kasaï Oriental   :              4 cas ;
  • Maniema            :              4 cas ;
  • Tshuapa              :              2 cas.
  • Haut-Lomami    :              1 cas :
  • Kasaï                    :              1 cas ;
  • Kasaï Central     :              1 cas ;
  • Kwango                              :              1 cas ;

L’article Covid-19 en RDC : 121 nouveaux cas confirmés, dont 104 à Kinshasa, 8 au Nord-Kivu et 8 dans le Sud-Kivu jeudi est apparu en premier sur Matininfos.NET – Information de la RDC en toute impartialité.

Source: Matininfos

Source : African Media Agency (AMA)

Read More
Building resilient communities through investments in water, sanitation and hygiene (WASH) programs & services
November 20, 2020 | 0 Comments

NAIROBI, Kenya, November 19, 2020,-/African Media Agency (AMA)/-  In commemoration of World Toilet Day, it is crucial that local, national, and global leaders commit to improving sanitation for African communities. Access to adequate sanitation improves health outcomes by reducing communicable diseases such as neglected tropical diseases (NTDs), thereby creating stronger and more resilient communities. 

Investments in WASH programs and services can significantly improve the quality of life for rural communities in Africa

Neglected tropical diseases (NTDs) are a group of parasitic and bacterial infectious diseases affecting more than 1.7 billion of the world’s population, with about 40% of this burden concentrated in Africa. Two of the most common NTDs are intestinal worms and bilharzia, both of which are parasitic worm infections. People who are exposed to feces-contaminated soil are more susceptible to NTD infections. 

According to a report by the Economist Intelligence Unit (EIU) that was supported by the END Fund, eliminating NTDs requires concerted action that is tailored to local contexts. This includes better disease mapping data, integration with wider public health efforts, and programs to improve sanitation. Additionally, investments should be targeted at strengthening health systems across the board to make them more responsive and resilient to these diseases.

Investments in WASH programs and services can significantly improve the quality of life for rural communities in Africa

The benefits of improved sanitation extend beyond households to entire communities and cannot be overemphasized. With a lower number of illnesses, more adults can contribute to the economy while the younger population can stay healthy and in school. Thus, it is imperative that steps are taken to end the neglect of communities in need of proper sanitation.

The END Fund is committed to ending NTDs during our lifetime. Through its efforts, the organization has reached many vulnerable and marginalized communities across Africa. During the COVID-19 pandemic, the END Fund established a COVID-19 response fund and invested in WASH programs and services to reduce communities’  exposure to communicable diseases such as COVID-19 and NTDs. In Ethiopia for instance, the END Fund worked with its partners to construct hand washing stations. To learn more about the END Fund’s work, watch this video.

Distributed by African Media Agency (AMA) on behalf of the END Fund.

About the END Fund
The END Fund is the only private philanthropic initiative solely dedicated to ending the five most common neglected tropical diseases (NTDs), which affect more than 1.7 billion people globally. It efficiently puts private capital to work, advocating for NTD programs that are innovative, integrated, and cost-effective. It facilitates strong partnerships with the private sector and has supported national disease control programs in 31 countries. Since its founding in 2012, with its partners, the END Fund has provided over 920 million donated treatments worth over $1 billion, over 17,000 surgeries for people suffering from the effects of the advanced stages of elephantiasis and trachoma, and trained more than 2.7 million people in NTD control and elimination efforts. Visit  www.end.org for more information.

Media contact
Tegan Mosugu
tmosugu@end.org

Source : African Media Agency (AMA)

Read More
World Toilet Day 2020: In the midst of a global COVID-19 pandemic, increased toilet hygiene awareness more important than ever
November 19, 2020 | 0 Comments


By Wambui Gichuri*

Wambui Gichuri is the African Development Bank’s Acting Vice President for Agriculture, Human and Social Development and also holds the position of Director for Water Development and Sanitation. She oversees the Bank’s water sector program of over $4.5 billion, covering 44 countries and multinational projects.

This year’s World Toilet Day observance comes in the midst of COVID-19. The gravity of the COVID-19 pandemic’s global spread heightens awareness about the important health benefits of appropriate toilet hygiene across Africa. Never has this been more pertinent than as we observe World Toilet Day.

While promising results on the vaccine front are underway,  a primary effective, preventive measure against the disease is basic handwashing with soap. Everyone must have sustainable sanitation, alongside clean water and handwashing facilities, to help protect and maintain our health security and stop the spread of deadly infectious diseases such as COVID-19, cholera and typhoid, among others.

The effects of this behavior change in hygiene practices will take some time to quantify. According to the British medical journal, the Lancet, handwashing practices in Africa have improved tremendously since the outbreak of COVID-19, with access to handwashing stations noticeably increasing in community centers, schools, markets, bus terminals, and other public spaces in rural and urban areas.

The Bank’s water, sanitation and hygiene (WASH) interventions across the continent have emphasized the importance of basic sanitation, as well as the health, economic, and environmental benefits that communities gain from it. In the fight to curb the spread of COVID-19, the Bank is ramping up these messages and the funding to expand the impacts of WASH programs.

In Africa, 60% of the population – about 715 million people – still don’t have access to basic sanitation, according to a Joint Monitoring Report from the World Health Organization and UNICEF. To address these water and sanitation challenges, the Bank has invested $6.2 billion over the last decade toward promoting universal and equitable access to safe and affordable drinking water, as well as to improved sanitation. An estimated 52 million people gained access to improved water supply and sanitation services due to these investments. Over the next 12 years, the Bank’s water sector investments aim to provide an additional 154 million people with these services across Africa. We are also advocating for more private sector participation as an option for sustainable management and financing of water services.

The Bank and the African Water Facility in 2019 launched the development of the African Urban Sanitation Investment Fund, an initiative to promote innovation and inclusive sanitation services for sub-Saharan Africa’s urban inhabitants.  The Bill and Melinda Gates Foundation is supporting the development of the initiative. It seeks to accelerate the pace of achieving Target 6.2 of the Sustainable Development Goals for sanitation in African

countries by fostering citywide inclusive sanitation, focusing on the poor and providing safe access to women and girls.

The African Water Facility has promoted innovative urban sanitation projects focusing on low-income groups and disseminated knowledge products on acceptable practices across Africa.

One particular success is the Bank co-funded “Toilets for All” project in Sokode, Togo. The small town of 100,000 people located 350 kilometers outside the capital, Lome, applied innovation and microcredit facilities to improve and expand sanitation services.Completed in 2018, the project constructed 688 private toilets in Sokode, thereby increasing access to improved sanitation by 6%. The African Water Facility funded $1.4 million out of its total cost of $1.88 million.  A community-based microcredit system provides household toilet installation services to this day.

The program also acquired a truck for safely emptying fecal sludge from on-site sanitation technologies, like septic tanks and transporting the sludge for treatment, use, or disposal. Neighborhood committees operate an installment payment program for eligible residents to pay for fecal sludge services.

The project’s new sludge treatment plant converts waste into fertilizer, which is sold to farmers. The plant also shares its solar-powered pumped water supply system with a neighboring village that previously had no access to potable water.

The Toilets for All initiative is making a difference in the lives of our people, and it is an example of the meaningful, community-centered and inclusive sanitation and fecal sludge management development that we are scaling up through funding and advocacy across Africa.

So as we mark World Toilet Day amidst the COVID-19 pandemic, the Bank is urging its African member governments and development partners to make greater efforts to provide access to adequate sanitation and hygiene for all, and for an end to open defecation in Africa by 2030.

*Wambui Gichuri is the African Development Bank’s Acting Vice President for Agriculture, Human and Social Development and also holds the position of Director for Water Development and Sanitation. She oversees the Bank’s water sector program of over $4.5 billion, covering 44 countries and multinational projects.

Read More
RDC: Enfin l’épidémie d’Ebola éradiquée dans l’Équateur
November 18, 2020 | 0 Comments

C’est le ministre à la santé qui a fait cette annonce. Docteur Eteni Longondo ce mercredi 18 Novembre lors d’un point de presse affirme ceci que

 » En ce mercredi 18 Novembre 2020, je suis heureux de déclarer solennellement la fin de la 11eme épidémie de la maladie à virus Ebola dans la province de l’Equateur en RDC « , déclare-t-il.

Après plus de 45 jours successifs sans enregistrer des nouveaux cas de cette épidémie, les docteurs Muyembe et Eteni Longondo viennent de déclarer la fin de cette maladie sur toute l’étendue nationale.

Par ailleurs, le ministre Longondo parle de la création de 11 laboratoires dans la province de l’équateur.

Profitant de cette occasion, le ministre à salué singulièrement l’engagement du gouverneur de la province, mes vivres félicitations ainsi à qui je présent  », précise-t-il.

Pour rappel, c’est depuis 2009 que cette maladie à été décore en RDC et est et plus particulièrement la partie Est du pays.

Jules Ninda

L’article RDC: Enfin l’épidémie d’Ebola éradiquée dans l’Équateur est apparu en premier sur Matininfos.NET – Information de la RDC en toute impartialité.

Source: Matininfos

Source : African Media Agency (AMA)

Read More
Merck Foundation marks “World Diabetes Day 2020” in partnership with African First Ladies and Ministries of Health by building Diabetes and hypertension care capacity nationwide
November 14, 2020 | 0 Comments
Merck Foundation to expand their ‘Diabetes Blue Points Program’ to more countries across Africa, Asia and Latin America.

Merck Foundation  has enrolled about 500 doctors from 39 countries to one-year diploma and two-year master degree to build Diabetes, cardiovascular preventive and endocrinology capacity across Africa, Asia and Latin America; Merck Foundation to expand their ‘Diabetes Blue Points Program’ to more countries across Africa, Asia and Latin America.

Merck Foundation, the philanthropic arm of Merck KGaA Germany marks ‘World Diabetes Day 2020’ by continuing their strategy to provide specialty training for African, Asian and Latin American doctors to better manage diabetes, hypertension and endocrinology patients.

Dr. Rasha Kelej, CEO of Merck Foundation and One of 100 Most Influential Africans (2019, 2020) explained, “At Merck Foundation, we mark ‘World Diabetes Day’ every day by providing One year diploma and two year master degree in Diabetes, endocrinology and cardiovascular preventive medicines to doctors as part of “Merck Foundation Diabetes Blue Points Program” in partnership with African First Ladies, Ministries of Health and Medical Societies. I am very proud to announce that around 500 Doctors from 39 countries across Africa, Asia and Latin America, have been enrolled to these courses. Our aim is to improve access to quality and equitable Diabetes, Hypertension and endocrinology care across the three continents. We will expand to more countries in the coming year”.

Merck Foundation is providing for One-Year Postgraduate Diploma and two year master degree in Diabetes, Endocrinology and Preventative Cardiovascular Medicines from University from UK. Merck Foundation also enrolls doctors for ‘Master course in the Clinical Management of Diabetes’ in 4 languages- English, French, Portuguese and Spanish, endorsed by Diabetes UK to improve access to quality and equitable diabetes care for African countries and Latin American countries.

So far, Merck Foundation has already enrolled 491 candidates for these courses from 39 African and Asian Countries including BangladeshBotswana, Burundi, CARCambodia, CameroonChad, Congo Brazzaville, DR Congo, Ethiopia, Gabon, Gambia, GhanaGuinee Conakry, Indonesia, Kenya, Liberia, Malaysia, Mauritius, Mozambique, Myanmar, Namibia, Nepal, Niger, Nigeria, Peru, Philippines, Rwanda, Senegal, Sierra Leone, South Africa, Sri Lanka, Sudan, Tanzania, UAE, Uganda, Vietnam, Zambia and Zimbabwe.

Some of these countries never had a Diabetologist before such as in Liberia where Merck Foundation together without Liberia First Lady provide specialty training to have the first diabetologists in public sector in Liberia. In addition to many other specialists who will be the first in Liberia, after graduating, such as: Sexual  and reproductive health, endocrinology, cardiovascular preventive medicines, respiratory medicines, fertility specialists and Embryologist.

“It is important to mention here that over 120 doctors have successfully completed the specialty training till today. The trained doctors will be able to establish diabetes clinic in their Health Centre or Hospital with the aim to help prevent and manage the disease in their respective communities. This will significantly help the people living with health conditions like diabetes, hypertension and heart diseases. We must not forget that they also fall under the coronavirus high risk group”, added Dr. Rasha Kelej.

Dr. Beata Iyaloo Haulofu from Namibia, candidate enrolled for PG Diploma Diabetes says, “I am very happy to be a part of ‘Merck Foundation Diabetes Blue Points Training Program’. This program will enable me to properly manage the patients, thereby reducing the morbidity and mortality associated with this health burden”.

Dr Niyonsenga Simon Pierre from Rwanda, candidate undergoing MSc diabetes states, “I feel fortunate to be a part of this beneficial course. I thank Merck Foundation for this opportunity. This will help me to advance my clinical knowledge and provide my expertise to the people of my country”.

*Merck Foundation
Read More
1 2 3 63